News for CHMA Stock

SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer Pulmatrix appoints Director Anand Varadan Chiasma Announces Submission of Marketing Authorization Application for MYCAPSSA® to the European Medicines Agency Chiasma Presents Positive Patient-Reported Outcomes Data from its MPOWERED™ Phase 3 Trial Comparing MYCAPSSA® to Long-Acting Injectables for the Maintenance Treatment of Adults with Acromegaly Chiasma to Present Encore and New Data from MPOWERED™ Phase 3 Trial at Upcoming e-ECE and AACE Virtual Conferences Chiasma Reports First Quarter Financial Results and Announced Agreement to Merge with Amryt Amryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases Chiasma to Report First Quarter Financial Results on May 6, 2021 Chiasma Presents Long-Term Safety and Efficacy Data from the Open-Label Extension Study of its CHIASMA OPTIMAL Phase 3 Trial Evaluating MYCAPSSA® in Patients with Acromegaly at ENDO 2021 Chiasma Presents New Positive Data for MYCAPSSA from Phase 3 Trial MPOWERED™ for the Maintenance Treatment of Acromegaly at ENDO 2021 Chiasma to Present New Data from Two Phase 3 Trials, CHIASMA OPTIMAL and MPOWERED™, at ENDO 2021 Chiasma Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate Update Chiasma to Participate in the H.C. Wainwright Global Life Sciences Conference Chiasma to Report Fourth Quarter 2020 Results on March 4 Chiasma Announces Hiring of John Doyle as Chief Financial Officer Chiasma Provides Corporate Update and Previews Expected 2021 Milestones Chiasma to Participate in Two Investor Conferences in December Chiasma to Host an Expert Panel on Acromegaly and the MPOWERED® Phase 3 Trial Results Chiasma Announces Positive Topline Results from the MPOWERED™ Phase 3 Clinical Trial Comparing MYCAPSSA® (octreotide capsules) to Long Acting Injectables for the Maintenance Treatment of Adults with Acromegaly Chiasma to Participate in the Jefferies Virtual London Healthcare Conference Chiasma Reports Third Quarter 2020 Results and Provides MYCAPSSA Launch Update Chiasma Reinforces Commitment to People with Acromegaly and Advocacy Organizations on Acromegaly Awareness Day Chiasma to Report Third Quarter 2020 Results on November 5 Chiasma Announces U.S. Commercial Launch and Availability of MYCAPSSA®, the First and Only Oral Somatostatin Analog for Patients with Acromegaly Chiasma Reports Second Quarter 2020 Results and Significant Progress on Launch Preparedness Chiasma Announces 48-Week Safety and Efficacy Data from the Open-Label Extension Study of its CHIASMA OPTIMAL Phase 3 Trial Evaluating MYCAPSSA® in Patients with Acromegaly Chiasma Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants Chiasma Reports First Quarter 2020 Financial Results Chiasma to Report Second Quarter 2020 Results on August 10 Chiasma Announces Pricing of a Public Offering of $70 Million of Common Stock and Pre-Funded Warrants Chiasma Announces FDA Approval of MYCAPSSA® (Octreotide) Capsules, the First and Only Oral Somatostatin Analog Chiasma To Report First Quarter Financial Results On May 7, 2020